GT Gain Therapeutics SA, a Lugano, Switzerland-based preclinical stage biotech company, closed a €2.5M Series A financing.
– VitaTech S.A. (€1.1Mio),
– Helsinn Investment Fund S.A. (€1Mio), and
– TiVenture S.A. (€0.4).
The company intends to use the funds to:
– further support the development of its most advanced programs and namely GM1 Gangliosidosis, Gaucher Disease and GBA-related Parkinson Disease,
– accelerate the identification of clinical candidates to be tested in first-of-human studies.
Established in 2017, Gain Therapeutics is a preclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of diseases using the proprietary SEE-Tx® technology. The company has several discovery programs in lysosomal storage diseases and CNS indications at various stages of development, all of which validate the platform and offer partnering opportunities.
Gain also has a branch in Barcelona.